Skip to content
RushPR News – Lifestyle
Author:
ORIC Pharmaceuticals
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
July 14, 2026
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 5, 2026
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
May 27, 2026
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
May 4, 2026
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026
←
Previous Page
1
2